Semaglutide

Business

Novo Nordisk Pivots: Oral Wegovy Launch, Job Cuts, and a Cell Therapy Bet Reshape Its Future

Novo Nordisk charts a bold new course, launching a pivotal oral obesity drug while restructuring its workforce and deepening its investment in next-generation cell therapies for metabolic diseases.

Business

Eli Lilly Commits $3.5 Billion to Pennsylvania, Creating 850 Jobs in Major Life Sciences Push

Pharmaceutical leader Eli Lilly will build a new manufacturing facility in Lehigh County, marking the largest life sciences investment in Pennsylvania history and bolstering U.S. production of next-generation weight-loss drugs.

Business

Novo Nordisk's Wegovy Pill Sees Strong Uptake with Over 26,000 Prescriptions in Second Week

Newly launched oral weight-loss drug Wegovy from Novo Nordisk recorded more than 26,000 U.S. prescriptions in its second full week, signaling robust early demand as competition with Eli Lilly intensifies.